10-K · March 10, 2026
Apyx reported accelerating commercial traction in 2025 driven by the AYON launch and higher product sales, generating record Q4 revenue of $19.2M and implied full-year revenue of about $52.0M. Cost actions reduced…
Earnings analysis · 10-Q
APYX earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Apyx Medical Corporation reported strong Q1 2026 results with revenue of $12.5 million, surpassing expectations of $10.9 million, and a narrower EPS loss of $0.05 compared to an estimated loss of $0.11. The surgical…
Read full summary
Apyx Medical Corporation reported strong Q1 2026 results with revenue of $12.5 million, surpassing expectations of $10.9 million, and a narrower EPS loss of $0.05 compared to an estimated loss of $0.11. The surgical aesthetics segment saw significant growth, prompting a raise in full-year revenue guidance to $59-$60 million, indicating positive momentum in their product lineup.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.05
- Gross margin
- 63.5%
What stood out
-
Revenue Exceeds Estimates
Q1 2026 revenue reached $12.5 million, exceeding the expected $10.9 million by 14.3%.
-
Narrowed EPS Loss
Diluted EPS loss was reported at $0.05, outperforming the estimated loss of $0.11 by 54.5%.
-
Segment Growth in Surgical Aesthetics
Sales in the Surgical Aesthetics segment grew by 36.1%, totaling $10.7 million in Q1 2026.
-
Improved Gross Margin
Gross margin increased to 63.5%, up from 60.1% year-over-year.
-
International Sales Surge
International sales increased by 62.9%, making up 35.1% of total revenue.
-
Increased Guidance for FY2026
Revenue guidance raised to $59-$60 million from a previous $57.5-$58.5 million.
What to watch
-
Ongoing Net Losses
The company continues to incur net losses, totaling approximately $0.6 million in Q1 2026.
-
Operational Funding Dependence
Management noted that operational funding is contingent on product sales and potential future financing options.
-
Market Competition Risks
Increased competition within the aesthetic market due to GLP-1 medications potentially affecting growth.
Management's outlook
Raised fiscal year 2026 revenue guidance from $57.5-$58.5 million to $59-$60 million.
Earlier filings 4
10-Q · November 6, 2025
Apyx reported Q3 sales of $12.877M (up $1.390M or ~12.1% YoY from $11.487M) with gross profit of $8.297M and gross margin expanding to ~64.4%. Operating loss narrowed to $(832)k (vs $(3.635)M a year ago) and diluted…
10-Q · August 7, 2025
Apyx reported Q2 2025 sales of $11.373M and GAAP diluted EPS of $(0.09), roughly in line with consensus but down versus Q2 2024. Profitability and cash flow are improving: gross margin expanded to 62.3% and operating…
10-Q · May 9, 2024
Apyx reported revenue of $10.244M for Q1 2024, down 15.6% year-over-year, driven by a 23.1% decline in Advanced Energy sales (to $7.453M) partially offset by a 13.8% increase in OEM sales (to $2.791M). Gross profit…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.